Skip to main content
Premium Trial:

Request an Annual Quote

Helicos Snags Steve Lombardi from Affy; Wellcome Trust's Michael Morgan Joins Genome Canada as CSO; Accelrys CFO Resigns; and Others

NEW YORK (GenomeWeb News) - Steve Lombardi has joined Helicos BioSciences as senior vice president of marketing.
Lombardi most recently served as a senior vice president at Affymetrix, where he was responsible for corporate development, product R&D and marketing, and corporate marketing between 2002 and 2006.
Prior to Affymetrix, Lombardi worked for 16 years at Applied Biosystems as a marketing manager and as an executive. From 1989 to 1998, Lombardi managed ABI's DNA sequencing and genetic analysis business.

Genome Canada has appointed Michael Morgan as chief scientific officer.

Morgan was formerly chief executive of the Wellcome Trust Genome Campus. He graduated in biochemistry from Trinity College, Dublin, and obtained his PhD from Leicester University for studies of microbial carbohydrate metabolism. He joined the Wellcome Trust in 1983.
At the Wellcome Trust, Morgan was responsible for the development of several initiatives, including the International Human Genome Sequencing Project, the Mouse Sequencing Project, the UK Synchrotron, DIAMOND, the SNP Consortium, and the Structural Genomics Consortium.

David Sankaran is resigning as senior vice president and chief financial officer of Accelrys, the company said this week.

Sankaran will continue in his role and assist the company with the search for a new CFO until Aug. 31.

Ciphergen Biosystems has established a scientific advisory board with five members:

Robert Bast, vice president for translational research and a professor at the University of Texas MD Anderson Center; Daniel Chan, a professor of pathology, oncology, urology, and radiology, and the director of the Center for Biomarker Discovery at the Johns Hopkins University School of Medicine; Ian Jacobs, director of the Department of Gynecological Oncology and the Institute of Women's Health at University College London; Joyce Schwartz, vice president and chief laboratory officer of Quest Diagnostics; and William Wallen, senior vice president and chief scientific officer of Idexx Laboratories.

Rob Martienssen, a faculty member of Cold Spring Harbor Laboratory and scientific co-founder of Orion Genomics, has been appointed a Fellow of the Royal Society of London.

Martienssen was elected to the society "in recognition of his outstanding contributions to understanding epigenetic control of gene expression," according to a statement from Orion.  
Martienssen received his BA in Natural Sciences (Genetics) from Cambridge University, and his PhD from the Plant Breeding Institute and Cambridge University.

Matritech has elected Bruce Lehman to its board of directors. Lehman is the co-founder and CEO of LehmanMillet, a marketing services firm for the medical device and diagnostics industry.

Lehman has been a member of the Biomedical Marketing Association since 1982, a member of its board of directors since 1996, president in 2004-2005, and currently serves as immediate past president. He was invited to join the Harvard-MIT Division of Health Sciences and Technology (HST) Advisory Council in 2001 and has served on the HST Advisory Board since 2003.

Alnylam Pharmaceuticals has appointed Saraswathy (Sara) Nochur to the position of vice president of regulatory affairs.

Nocur was most recently vice president of regulatory affairs at The Medicines Company. Prior to that, she held positions in regulatory affairs at CereMedix, BioTrack, and DynaGen.

David Gelfand has joined the scientific advisory board of Innovative Biosensors.

Gelfand most recently served as vice president of discovery research at Roche Molecular Systems. Prior to that, he was with Cetus, where he founded the company's recombinant molecular research division in 1976.

Evan Jones will retire as chairman and CEO of Digene during the company's 2007 fiscal year, the company said this week.  

 Jones will remain a member of the Digene board of directors.
The board's nominating and corporate governance committee is overseeing the search for a new CEO, "and is in the process of retaining an executive search firm to conduct this search," the company said

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.